No Data
No Data
Express News | Exagen Reaches 1M Patient Tested Vy AVISE CTD Milestone
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Exagen Inc. (NASDAQ:XGN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the Avise® Ctd Platform
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform